Xtant Medical Holdings Inc
Research Xtant Medical Holdings Inc (XTNT) on Bullrun: valuation model: 27.4% overvalued, market cap USD 59.74M, P/E 39.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXTNT
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal27.4% overvalued
- Market capUSD 59.74M
- P/E39.1
- Financial periodFY2025
- RevenueUSD 133.93M
- Revenue growth14.2%
- Net incomeUSD 4.97M
- Free cash flowUSD 10.16M
- Gross margin62.9%
Valuation Snapshot
Bullrun's latest valuation model marks Xtant Medical Holdings Inc as 27.4% overvalued; latest market cap is USD 59.74M; P/E is 39.1.
About Xtant Medical Holdings Inc
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization;
Frequently asked questions
Is Xtant Medical Holdings Inc overvalued or undervalued?
Bullrun's valuation model currently marks Xtant Medical Holdings Inc as 27.4% overvalued.
What is Xtant Medical Holdings Inc's market cap?
Xtant Medical Holdings Inc's market capitalization is USD 59.74M.
What is Xtant Medical Holdings Inc's P/E ratio?
Xtant Medical Holdings Inc's price-to-earnings (P/E) ratio is 39.1.
What does Xtant Medical Holdings Inc do?
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix;